TAT 2012 in Amsterdam, The Netherlands, will be the tenth meeting in the series named in full "International Symposium on Targeted Anticancer Therapies". Like all TAT meetings held since 2005, TAT 2012 will be another official ESMO Partnership Meeting. TAT 2012 is offered by the Amsterdam-based NDDO Education Foundation, and is co-sponsored by the U.S. National Cancer Institute - Center for Cancer Research.

TAT meetings are characterized by their focus on targeted cancer therapeutics, in particular the most promising ones in the late preclinical and early clinical development stages. TAT 2012 will offer excellent opportunities for the presentation and discussion of ongoing and completed phase 1 studies in a highly interactive setting. Apart from being of importance to everyone involved in anticancer drug development on a daily basis, the TAT 2012 program will also be of educational value to oncologists wishing to stay abreast of emerging new treatment options.

Distinguishing features of TAT 2012:

Highly focused on early phase development of promising targeted agents for cancer therapy
Medium-sized event (400-600), creating excellent possibilities for peer-to-peer interactions
Similar numbers of participants from academia and industry
No paralllel sessions, avoiding the need to make difficult choices
Attention to methodological and regulatory issues in new drug development
Ample opportunityto present your own work in front of an international expert audience

Location